Regulus Therapeutics: Strong Industry, Solid Earnings Estimate Revisions
One stock that might be an intriguing choice for investors right now is Regulus Therapeutics Inc. RGLS.This is because this security in the Medical — Drugs space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical — Drugs space as it currently has a Zacks Industry Rank of 56 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.
Meanwhile, Regulus Therapeuticsis actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.
In fact, over the past month, current quarter estimates have narrowed from a loss of 30 cents per share to a loss of 26 cents per share, while current year estimates have narrowed from a loss of $1.25 per share to a loss of $1.20 per share. This has helped RGLS to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position.
So, if you are looking for a decent pick in a strong industry, consider Regulus Therapeutics. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
REGULUS THERAP (RGLS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
